Nash

Callinex Announces Follow-up on Silver Discoveries at the Nash Creek Project in Bathurst Mining District, New Brunswick

Retrieved on: 
Thursday, July 23, 2020
Physical sciences, Chemistry, Natural sciences, CNX, Nash Motors, Porterfield, Nash, Zinc

VANCOUVER, BC, July 23, 2020 /PRNewswire/ - Callinex Mines Inc. (the "Company" or "Callinex") (TSXV: CNX) (OTC: CLLXF) is pleased to announce it plans to commence a soil sampling campaign (the "Campaign") at its 100% owned Nash Creek Project (the "Project") located within the Bathurst Mining District of New Brunswick ( See Figure 1 ).

Key Points: 
  • VANCOUVER, BC, July 23, 2020 /PRNewswire/ - Callinex Mines Inc. (the "Company" or "Callinex") (TSXV: CNX) (OTC: CLLXF) is pleased to announce it plans to commence a soil sampling campaign (the "Campaign") at its 100% owned Nash Creek Project (the "Project") located within the Bathurst Mining District of New Brunswick ( See Figure 1 ).
  • Mr. Porterfield continued, "The silver discoveries at Nash Creek have come at a favorable time for the Company and its shareholders.
  • Limited historic regional silver, lead and zinc soil sampling has been completed by previous explorers at the Nash Creek Project.
  • This historic data along with the newly acquired Induced Polarization survey results were utilized to target the two recently announced silver discoveries.

Non-Alcoholic Steatohepatitis (NASH) Drugs Market, 2029 - Featuring Profiles of Bristol Myers Squibb, Gilead Sciences, Allergan (Abbvie), Intercept Pharma, Galmed Pharma, and Genfit

Retrieved on: 
Thursday, July 16, 2020
Medical specialties, Medicine, Hepatitis, Health, Steatohepatitis, Pharmaceutical industry, Non-alcoholic fatty liver disease, Nash, Drug, Medication, Carboxylic acids

The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$ 84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029.

Key Points: 
  • The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$ 84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029.
  • The global non-alcoholic steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs.
  • The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH.
  • The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs submarkets.

Glympse Bio Announces $46.7 Million Series B Financing

Retrieved on: 
Wednesday, July 15, 2020
Hepatitis, Life sciences, Medicine, Steatohepatitis, Biotechnology, Non-alcoholic fatty liver disease, Sangeeta, Bhatia, Nash, Biosensor, Scientists

CAMBRIDGE, Mass., July 15, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing.

Key Points: 
  • CAMBRIDGE, Mass., July 15, 2020 /PRNewswire/ -- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing.
  • In connection with the financing, Steven Kafka, Ph.D., Managing Partner at Section 32, and George Zachary, General Partner at CRV, will join the Glympse Board of Directors.
  • The proceeds from the financing will support continued development of Glympse's novel biosensor platform in Non-Alcoholic Steatohepatitis (NASH), a disease that impacts 16 million people in the U.S. and 100 million worldwide.
  • Founded in 2015, Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia.

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 14, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Nash, Hepatitis

The "Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029)" report has been added to ResearchAndMarkets.com's offering.
  • The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$ 84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029.
  • The global non-alcoholic steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs.
  • The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs submarkets.

Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001

Retrieved on: 
Monday, June 29, 2020
Dial, Nash, Toll-free telephone number, Economy of the United States, Decades

The company will host a conference call and webcast with slide presentation at 4:30 p.m.

Key Points: 
  • The company will host a conference call and webcast with slide presentation at 4:30 p.m.
  • To access the call via dial-in, please dial 1-866-652-5200 (U.S. toll free) or 1-412-317-6060 (international) five minutes prior to the start time.
  • Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health of NASH patients.
  • The company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial.

NASHNET Celebrates International NASH Day with an Educational Podcast Series

Retrieved on: 
Friday, June 12, 2020
Medical specialties, Medicine, RTT, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Diabetes, Hepatitis, Metabolic syndrome, Nash, Liver disease

NEW YORK, June 12, 2020 /PRNewswire/ --In recognition of International NASH Day (June 12th), NASHNET has released a four-part podcast education series to promote education and increase awareness of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) outside of the hepatology community.

Key Points: 
  • NEW YORK, June 12, 2020 /PRNewswire/ --In recognition of International NASH Day (June 12th), NASHNET has released a four-part podcast education series to promote education and increase awareness of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) outside of the hepatology community.
  • International NASH Day, organized by the Global Liver Institute (GLI), is an annual event dedicated to raising awareness about NAFLD and NASH and the actions that patients and providers can take to address these diseases.
  • This year, GLI will host six virtual NASH panels relating to: NASH as a public health challenge, pediatric NASH/NAFLD, NASH and obesity, beyond the biopsy and the role of non-invasive technologies in NASH, NASH as a metabolic syndrome, and NASH and liver cancer.
  • To listen to the NASHNET educational podcast series, visit www.nashnetwork.org/blog-posts .

Global Liver Institute’s International NASH Day Convenes 80 Partner Organizations and 30 Speakers to Declare Urgency of Combatting Parallel Epidemics of Liver Disease and COVID-19

Retrieved on: 
Friday, June 12, 2020
Medical specialties, Medicine, Hepatology, Nash, Liver transplantation, Liver, Organ transplantation, Hepatitis, RTT

For this reason, people with NASH are often unaware of their liver condition until the disease progresses.

Key Points: 
  • For this reason, people with NASH are often unaware of their liver condition until the disease progresses.
  • NASH is the second leading cause of liver transplant in the US and is predicted to become the leading cause.
  • The Global Liver Institutes International NASH Day plays a significant role in building awareness of screening, NASH education and advocacy, and taking actions that will significantly impact this global epidemic."
  • For additional information on International NASH Day, visit www.international-nash-day.com
    Support the IND social media campaign using hashtag #NASHday and Twitter @GlobalLiver.

CN Bio and Cambridge University Identify Novel Regulatory Pathway Driving NASH

Retrieved on: 
Tuesday, June 9, 2020
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Wellcome Sanger Institute, Wellcome Trust, Nash, BIOS

The collaborative work uses CN Bios NASH model to help elucidate the complex cellular mechanisms that cause liver fibrosis.

Key Points: 
  • The collaborative work uses CN Bios NASH model to help elucidate the complex cellular mechanisms that cause liver fibrosis.
  • Contributing organisations include: University of Cambridge, Newcastle University, National & Kapodistrian University of Athens, Nordic Bioscience A/S, Sorbonne Universit, Imperial College London and Wellcome Trust Sanger Institute.
  • The paper illustrates the direct translation between CN Bios NASH assay, human clinical studies and in vivo mouse models.
  • Dr David Hughes, CEO, CN Bio, commented: Increasing global levels of obesity are paralleled with growing numbers of NASH patients.

Akero Therapeutics To Present At The Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 26, 2020
Medical specialties, Hepatitis, Medicine, Steatohepatitis, RTT, Non-alcoholic fatty liver disease, Nash

(Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today announced that members of the management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference at 10:30 a.m.

Key Points: 
  • (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today announced that members of the management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference at 10:30 a.m.
  • A live webcast will be available through the investor relations section of the Company's website at www.akerotx.com .
  • Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients.
  • Akero Therapeutics is headquartered in South San Francisco, CA.

New Preclinical Models for NASH Provide Strong Clinical Relevance and Shortened Timelines

Retrieved on: 
Tuesday, May 26, 2020
Health, Science, Pharmaceutical, Research, Clinical trials, Nash, Economy of the United States, Decades, BioDuro, Advent International

Accordingly, biopharma companies are heavily targeting NASH; however, progress has been limited by preclinical models that do not accurately mimic NASH disease complexity or take extremely long to develop the disease, making them impractical for preclinical timelines.

Key Points: 
  • Accordingly, biopharma companies are heavily targeting NASH; however, progress has been limited by preclinical models that do not accurately mimic NASH disease complexity or take extremely long to develop the disease, making them impractical for preclinical timelines.
  • The new NASH models we have developed represent considerable progress for NASH drug development by providing clinically translatable biological test systems that can be performed in pragmatic timelines, said Xiang Li, DPhil, Senior Vice President, Integrated Biology at BioDuro.
  • These mouse and hamster models add to our current NASH panel, providing a full spectrum of NASH disease models for our biopharma partners to help address their different needs.
  • In addition to the new models that BioDuro has launched, the company has 3 other NASH models to meet the needs and preferences of clients.